en POLSKI
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2024
vol. 99
 
Share:
Send email
Share:
abstract:
Original paper

The impact of the COVID-19 pandemic on the incidence and clinical course of acute post-streptococcal glomerulonephritis in children – single-centre experience

Artur Janek
1
,
Martyna Szuster
1
,
Dawid Jasiński
1
,
Magdalena Kleszyk
2
,
Magdalena Grześkowiak-Paszyna
2
,
Andrzej Badeński
1
,
Barbara Lewicka
3
,
Maria Szczepańska
1

  1. Department of Paediatrics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
  2. Department of Paediatric Nephrology with Dialysis Division for Children, Independent Public Clinical Hospital No. 1, Zabrze, Poland
  3. Department of Rehabilitation, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
Pediatr Pol 2024; 99 (3): 211-217
DOI: https://doi.org/10.5114/polp.2024.143268
Online publish date: 2024/09/30
View full text Get citation
 
PlumX metrics:
Introduction:
During the SARS-CoV-2 pandemic, a decrease in acute post-streptococcal glomerulonephritis (APSGN) cases was observed; however, as the pandemic subsided, reports of an increased number of diagnosed APSGN cases in the paediatric population emerged. The aim of our study was to compare the number of cases and the patient profile diagnosed with acute post-streptococcal glomerulonephritis in our centre before and after the COVID-19 pandemic.

Material and methods:
A retrospective study included 47 patients (21 females, 26 males) diagnosed with APSGN, hospitalised in our centre between 2013–2023. The parameters were compared between the group of patients diagnosed before and after the pandemic. Age at day of diagnosis, history of previous possible streptococcal infection, antistreptolysin O (ASO), C3, epidermal growth factor receptor levels at admission, the presence of the features of nephritic syndrome, the need for pharmacological treatment, and renal replacement therapy were analysed. Additionally, anthropometric measurements the C4 complement component were determined.

Results:
From 2013 to 2022, the average number of diagnosed APSGN cases per year was 3.67, increasing to 7 cases per year since 2022. A statistically significant difference in ASO level values at admission was observed between patients diagnosed with post-streptococcal glomerulonephritis before the pandemic (767 IU/ml) compared to those diagnosed after the pandemic (1362 IU/ml). No other statistically significant differences were found in the patient profile analysis.

Conclusions:
During the COVID-19 pandemic, no cases of APSGN were observed in our centre, probably due to the implemented personal protective measures and population isolation. After the COVID-19 pandemic, there was an increase in APSGN cases among children. The patient profile with diagnosis before and after the pandemic in terms of most parameters does not differ. The only significant difference was observed in ASO levels, which were higher in patients diagnosed after the pandemic compared to those diagnosed before the pandemic. Further research is needed.

keywords:

acute post-streptococcal glomerulonephritis (APSGN), Group A Streptococcus, post-pandemic COVID-19 infections